Find disease awareness content and relevant supporting materials

Ibrutinib is the first in-class, orally administered, Bruton's tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR).

The National Institute for Health and Care Excellence (NICE) has not recommended Imbruvica (ibrutinib) from Janssen Pharma for the treatment...

The FDA has approved an expansion to the U.S. Prescribing Information (PI) for Imbruvica (ibrutinib), from Janssen, based on data...

AbbVie announced that the FDA has approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)....

The past two decades have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL), particularly with the introduction of targeted therapies to clinical practice.

Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...

B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown.

An earlier recommendation by the UK's NICE did not recommend Imbruvica (ibrutinib), from Janssen, for routine NHS use to treat...

Janssen has submitted a Type II variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing...

Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib .